1. Home
  2. MMA vs LEXX Comparison

MMA vs LEXX Comparison

Compare MMA & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alta Global Group Limited

MMA

Alta Global Group Limited

HOLD

Current Price

$0.39

Market Cap

13.9M

Sector

N/A

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$4.75

Market Cap

16.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMA
LEXX
Founded
2013
2004
Country
Australia
Canada
Employees
N/A
7
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9M
16.5M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
MMA
LEXX
Price
$0.39
$4.75
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
81.6K
121.8K
Earning Date
05-20-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$0.35
52 Week High
$2.00
$1.55

Technical Indicators

Market Signals
Indicator
MMA
LEXX
Relative Strength Index (RSI) 33.44 94.25
Support Level $0.35 $0.69
Resistance Level $0.50 N/A
Average True Range (ATR) 0.03 0.17
MACD -0.01 0.26
Stochastic Oscillator 0.09 80.27

Price Performance

Historical Comparison
MMA
LEXX

About MMA Alta Global Group Limited

MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: